Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Subterminal hydroxyeicosatetraenoic acids: Crucial lipid mediators in normal physiology and disease states.

Shoieb SM, El-Sherbeni AA, El-Kadi AOS.

Chem Biol Interact. 2019 Feb 1;299:140-150. doi: 10.1016/j.cbi.2018.12.004. Epub 2018 Dec 10. Review.

PMID:
30543782
2.

Identification of 19-(S/R)Hydroxyeicosatetraenoic Acid as the First Endogenous Noncompetitive Inhibitor of Cytochrome P450 1B1 with Enantioselective Activity.

Shoieb SM, El-Sherbeni AA, El-Kadi AOS.

Drug Metab Dispos. 2019 Feb;47(2):67-70. doi: 10.1124/dmd.118.084657. Epub 2018 Nov 12.

PMID:
30420405
3.

DHA and 19,20-EDP induce lysosomal-proteolytic-dependent cytotoxicity through de novo ceramide production in H9c2 cells with a glycolytic profile.

Endo T, Samokhvalov V, Darwesh AM, Khey KMW, El-Sherbeni AA, Ei-Kadi AOS, Machida T, Hirafuji M, Seubert JM.

Cell Death Discov. 2018 Aug 20;4:29. doi: 10.1038/s41420-018-0090-1. eCollection 2018.

4.

The Role of Soluble Epoxide Hydrolase Enzyme on Daunorubicin-Mediated Cardiotoxicity.

Maayah ZH, Abdelhamid G, Elshenawy OH, El-Sherbeni AA, Althurwi HN, McGinn E, Dawood D, Alammari AH, El-Kadi AOS.

Cardiovasc Toxicol. 2018 Jun;18(3):268-283. doi: 10.1007/s12012-017-9437-8.

PMID:
29196978
5.

Differential eNOS-signalling by platelet subpopulations regulates adhesion and aggregation.

Radziwon-Balicka A, Lesyk G, Back V, Fong T, Loredo-Calderon EL, Dong B, El-Sikhry H, El-Sherbeni AA, El-Kadi A, Ogg S, Siraki A, Seubert JM, Santos-Martinez MJ, Radomski MW, Velazquez-Martinez CA, Winship IR, Jurasz P.

Cardiovasc Res. 2017 Dec 1;113(14):1719-1731. doi: 10.1093/cvr/cvx179. Review.

6.

Inhibition of Mid-chain HETEs Protects Against Angiotensin II-induced Cardiac Hypertrophy.

Elkhatali S, Maayah ZH, El-Sherbeni AA, Elshenawy OH, Abdelhamid G, Shoieb SM, El-Kadi AOS.

J Cardiovasc Pharmacol. 2017 Jul;70(1):16-24. doi: 10.1097/FJC.0000000000000494.

PMID:
28437282
7.

The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol.

Maayah ZH, Althurwi HN, El-Sherbeni AA, Abdelhamid G, Siraki AG, El-Kadi AO.

Mol Cell Biochem. 2017 May;429(1-2):151-165. doi: 10.1007/s11010-017-2943-y. Epub 2017 Mar 1.

PMID:
28251434
8.

Pharmacokinetics of metformin in the rat: assessment of the effect of hyperlipidemia and evidence for its metabolism to guanylurea.

Gabr RQ, El-Sherbeni AA, Ben-Eltriki M, El-Kadi AO, Brocks DR.

Can J Physiol Pharmacol. 2017 May;95(5):530-538. doi: 10.1139/cjpp-2016-0329. Epub 2016 Dec 15.

PMID:
28177686
9.

Microsomal cytochrome P450 as a target for drug discovery and repurposing.

El-Sherbeni AA, El-Kadi AO.

Drug Metab Rev. 2017 Feb;49(1):1-17. doi: 10.1080/03602532.2016.1257021. Epub 2016 Nov 22. Review.

PMID:
27819488
10.

Repurposing Resveratrol and Fluconazole To Modulate Human Cytochrome P450-Mediated Arachidonic Acid Metabolism.

El-Sherbeni AA, El-Kadi AO.

Mol Pharm. 2016 Apr 4;13(4):1278-88. doi: 10.1021/acs.molpharmaceut.5b00873. Epub 2016 Mar 10.

PMID:
26918316
11.

Ketoconazole Stereoisomers Differentially Induce Cytochrome P450 1A1 Between Human Hepatoma HepG2 and Mouse Hepatoma Hepa1c1c7 Cells.

Anwar-Mohamed A, El-Sherbeni AA, Hamdy DA, Korashy HM, Brocks DR, El-Kadi AO.

J Pharm Sci. 2016 Mar;105(3):1318-26. doi: 10.1016/j.xphs.2015.12.009. Epub 2016 Feb 6.

PMID:
26886340
12.

19-Hydroxyeicosatetraenoic acid and isoniazid protect against angiotensin II-induced cardiac hypertrophy.

Elkhatali S, El-Sherbeni AA, Elshenawy OH, Abdelhamid G, El-Kadi AO.

Toxicol Appl Pharmacol. 2015 Dec 15;289(3):550-9. doi: 10.1016/j.taap.2015.10.003. Epub 2015 Oct 8.

PMID:
26454030
13.

The role of epoxide hydrolases in health and disease.

El-Sherbeni AA, El-Kadi AO.

Arch Toxicol. 2014 Nov;88(11):2013-32. doi: 10.1007/s00204-014-1371-y. Epub 2014 Sep 24. Review.

PMID:
25248500
14.

Acute arsenic treatment alters arachidonic acid and its associated metabolite levels in the brain of C57Bl/6 mice.

Anwar-Mohamed A, Elshenawy OH, El-Sherbeni AA, Abdelrady M, El-Kadi AO.

Can J Physiol Pharmacol. 2014 Aug;92(8):693-702. doi: 10.1139/cjpp-2014-0136.

PMID:
25065748
15.

Characterization of arachidonic acid metabolism by rat cytochrome P450 enzymes: the involvement of CYP1As.

El-Sherbeni AA, El-Kadi AO.

Drug Metab Dispos. 2014 Sep;42(9):1498-507. doi: 10.1124/dmd.114.057836. Epub 2014 Jun 26.

PMID:
24969701
16.

Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy.

El-Sherbeni AA, El-Kadi AO.

Biochem Pharmacol. 2014 Feb 1;87(3):456-66. doi: 10.1016/j.bcp.2013.11.015. Epub 2013 Dec 1.

PMID:
24300133
17.

Determination of the dominant arachidonic acid cytochrome p450 monooxygenases in rat heart, lung, kidney, and liver: protein expression and metabolite kinetics.

El-Sherbeni AA, Aboutabl ME, Zordoky BN, Anwar-Mohamed A, El-Kadi AO.

AAPS J. 2013 Jan;15(1):112-22. doi: 10.1208/s12248-012-9425-7. Epub 2012 Nov 10.

18.

Chronic doxorubicin cardiotoxicity modulates cardiac cytochrome P450-mediated arachidonic acid metabolism in rats.

Alsaad AM, Zordoky BN, El-Sherbeni AA, El-Kadi AO.

Drug Metab Dispos. 2012 Nov;40(11):2126-35. doi: 10.1124/dmd.112.046631. Epub 2012 Aug 6.

PMID:
22867862
19.

Acute arsenic toxicity alters cytochrome P450 and soluble epoxide hydrolase and their associated arachidonic acid metabolism in C57Bl/6 mouse heart.

Anwar-Mohamed A, El-Sherbeni AA, Kim SH, Althurwi HN, Zordoky BN, El-Kadi AO.

Xenobiotica. 2012 Dec;42(12):1235-47. doi: 10.3109/00498254.2012.693971. Epub 2012 Jun 9.

PMID:
22680237

Supplemental Content

Loading ...
Support Center